[ad_1]
The Ministry of Health said it was a brand name for the treatment of larotrectinib, a drug that does not treat cancer completely or completely, as it has been mentioned, but which aims to control its growth and spread for as long as possible. It does not replace surgical, chemical and radiological treatments.
The study involved 55 cancer patients and carriers of a genetic mutation of TRK with a 13% complete response rate and a 62% partial response rate.
"This response did not last long for all patients.The disease developed in some study participants and continued to respond in 39% of patients after the first year of treatment, and some patients were operated on after taking the drug. "
The new treatment has recently been approved by the US Food and Drug Administration to treat specific cancer cases in people with a specific type of rare genetic mutations (TRK gene). This flare is observed in some tumors such as saliva, on the genetic mutation and does not tolerate or undergo surgery
An appropriate alternative to treatment and cases developed after treatment is scheduled.
[ad_2]
Source link
